Source: C19Study

A live and ongoing index of studies from around the world documenting the use of hydroxychloroquine in treatment at various stages of SARS-CoV-2 infection including pre-exposure prophylaxis and post-exposure prophylaxis is available at https://c19study.com/, that also states whether the outcome was positive or negative.

blank

Overwhelmingly, PrEP, PEP, and early treatment studies show high effectiveness of hydroxychloroquine, while late treatment shows mixed results.

blank

Older Updates can be found here:

C19study.com update: Now 88 international studies (51 peer reviewed) show positive hydroxychloroquine treatment outcomes

61 studies (37 peer reviewed) Early treatment studies are very positive – COVID deaths: 621, 206

C19 Study: 53 studies (31 peer reviewed) showing “very positive” results using HCQ as pre & post exposure prophylaxis & early treatment.






Related:

Belgium Study 8,075 patients: Low HCQ doses resulted in lower mortality in Covid patients

Italy Study 3,451 patients: Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

New Jersey Study of 1,274: Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19; A multi-center observational study where hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization

Belgium revisits: Hydrochloroquine has indeed been shown to decrease the production of pro-inflammatory cytokines, both ex vivo and in a pulmonary model.

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »